Acquired haemophilia A after alemtuzumab therapy

Marieke van der Zwan; Frank W.G. Leebeek; Yorick Sandberg; Marieke J.H.A. Kruip; Dennis A. Hesselink

doi:10.1111/hae.14107

Acquired haemophilia A after alemtuzumab therapy

Marieke van der Zwan^*, Frank W.G. Leebeek, Yorick Sandberg, Marieke J.H.A. Kruip, Dennis A. Hesselink

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

7 Citations (Scopus)

44 Downloads (Pure)

Original language	English
Pages (from-to)	e337-e339
Journal	Haemophilia
Volume	26
Issue number	6
DOIs	https://doi.org/10.1111/hae.14107
Publication status	Published - Nov 2020

Bibliographical note

Funding Information:
MvdZ declares no conflicts of interest. FWGL received research funding from CSL Behring, Shire/Takeda and uniQure. He is consultant for Biomarin, uniQure and Takeda of which fees got to the institution and is a DSMB member for Roche. MJHAK has received unrestricted research grants form Daiichi Sankyo, Boehringer Ingelheim, Bayer and Pfizer and speakers fee from Bayer. DAH has received grant support, lecture and consulting fees from Astellas Pharma and Chiesi Pharmaceuticals, as well as a lecture fee from Hikma Pharma and grant support from Bristol Myers‐Squibb.

Research programs

EMC OR-01

Access to Document

10.1111/hae.14107

Repub_129105.pdfFinal published version, 341 KB

http://hdl.handle.net/1765/129105

Cite this

@article{95aaca36621f4e7dbcbcfed8db86047a,

title = "Acquired haemophilia A after alemtuzumab therapy",

author = "{van der Zwan}, Marieke and Leebeek, {Frank W.G.} and Yorick Sandberg and Kruip, {Marieke J.H.A.} and Hesselink, {Dennis A.}",

note = "Funding Information: MvdZ declares no conflicts of interest. FWGL received research funding from CSL Behring, Shire/Takeda and uniQure. He is consultant for Biomarin, uniQure and Takeda of which fees got to the institution and is a DSMB member for Roche. MJHAK has received unrestricted research grants form Daiichi Sankyo, Boehringer Ingelheim, Bayer and Pfizer and speakers fee from Bayer. DAH has received grant support, lecture and consulting fees from Astellas Pharma and Chiesi Pharmaceuticals, as well as a lecture fee from Hikma Pharma and grant support from Bristol Myers‐Squibb. ",

year = "2020",

month = nov,

doi = "10.1111/hae.14107",

language = "English",

volume = "26",

pages = "e337--e339",

journal = "Haemophilia",

issn = "1351-8216",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "6",

}

TY - JOUR

T1 - Acquired haemophilia A after alemtuzumab therapy

AU - van der Zwan, Marieke

AU - Leebeek, Frank W.G.

AU - Sandberg, Yorick

AU - Kruip, Marieke J.H.A.

AU - Hesselink, Dennis A.

N1 - Funding Information: MvdZ declares no conflicts of interest. FWGL received research funding from CSL Behring, Shire/Takeda and uniQure. He is consultant for Biomarin, uniQure and Takeda of which fees got to the institution and is a DSMB member for Roche. MJHAK has received unrestricted research grants form Daiichi Sankyo, Boehringer Ingelheim, Bayer and Pfizer and speakers fee from Bayer. DAH has received grant support, lecture and consulting fees from Astellas Pharma and Chiesi Pharmaceuticals, as well as a lecture fee from Hikma Pharma and grant support from Bristol Myers‐Squibb.

PY - 2020/11

Y1 - 2020/11

UR - http://www.scopus.com/inward/record.url?scp=85088314119&partnerID=8YFLogxK

U2 - 10.1111/hae.14107

DO - 10.1111/hae.14107

M3 - Article

C2 - 32700327

SN - 1351-8216

VL - 26

SP - e337-e339

JO - Haemophilia

JF - Haemophilia

IS - 6

ER -

Acquired haemophilia A after alemtuzumab therapy

Bibliographical note

Research programs

Access to Document

Other files and links

Cite this